Mariner Wealth Advisors LLC lessened its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 14.1% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 32,578 shares of the company’s stock after selling 5,363 shares during the quarter. Mariner Wealth Advisors LLC’s holdings in Eli Lilly and were worth $2,681,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of the company. Ronna Sue Cohen boosted its position in shares of Eli Lilly and by 0.4% during the 2nd quarter. Ronna Sue Cohen now owns 2,466 shares of the company’s stock valued at $203,000 after acquiring an additional 9 shares during the last quarter. Accredited Investors Inc. boosted its position in shares of Eli Lilly and by 0.4% during the 2nd quarter. Accredited Investors Inc. now owns 3,259 shares of the company’s stock valued at $268,000 after acquiring an additional 14 shares during the last quarter. Northwest Quadrant Wealth Management LLC boosted its position in shares of Eli Lilly and by 0.5% during the 1st quarter. Northwest Quadrant Wealth Management LLC now owns 3,589 shares of the company’s stock valued at $290,000 after acquiring an additional 19 shares during the last quarter. Oakworth Capital Inc. boosted its position in shares of Eli Lilly and by 0.3% during the 2nd quarter. Oakworth Capital Inc. now owns 6,714 shares of the company’s stock valued at $552,000 after acquiring an additional 20 shares during the last quarter. Finally, Sfmg LLC boosted its position in shares of Eli Lilly and by 0.5% during the 2nd quarter. Sfmg LLC now owns 4,258 shares of the company’s stock valued at $350,000 after acquiring an additional 20 shares during the last quarter. Hedge funds and other institutional investors own 75.48% of the company’s stock.

In related news, major shareholder Lilly Endowment Inc sold 205,000 shares of Eli Lilly and stock in a transaction that occurred on Wednesday, October 4th. The stock was sold at an average price of $86.81, for a total transaction of $17,796,050.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, SVP Alfonso G. Zulueta sold 2,003 shares of Eli Lilly and stock in a transaction that occurred on Friday, November 10th. The shares were sold at an average price of $83.67, for a total value of $167,591.01. Following the sale, the senior vice president now owns 43,580 shares in the company, valued at $3,646,338.60. The disclosure for this sale can be found here. Insiders have sold 772,003 shares of company stock worth $64,837,441 over the last three months. Insiders own 0.20% of the company’s stock.

A number of analysts recently weighed in on the company. Credit Suisse Group downgraded Eli Lilly and from an “outperform” rating to a “neutral” rating and boosted their target price for the stock from $84.23 to $88.00 in a research report on Tuesday, October 10th. Piper Jaffray Companies restated a “buy” rating and issued a $103.00 target price on shares of Eli Lilly and in a research report on Thursday, August 31st. Zacks Investment Research upgraded Eli Lilly and from a “hold” rating to a “buy” rating and set a $95.00 target price for the company in a research report on Thursday, October 26th. Jefferies Group LLC restated a “buy” rating and issued a $89.00 target price (down previously from $94.00) on shares of Eli Lilly and in a research report on Thursday, August 24th. Finally, BMO Capital Markets set a $73.00 target price on Eli Lilly and and gave the stock a “sell” rating in a research report on Wednesday, November 1st. Three analysts have rated the stock with a sell rating, eight have given a hold rating and ten have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $89.76.

ILLEGAL ACTIVITY WARNING: This article was first posted by Daily Political and is the sole property of of Daily Political. If you are reading this article on another domain, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this article can be read at https://www.dailypolitical.com/2017/11/15/eli-lilly-and-company-lly-shares-sold-by-mariner-wealth-advisors-llc.html.

Eli Lilly and Company (NYSE:LLY) opened at $82.49 on Wednesday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.03 and a current ratio of 1.38. Eli Lilly and Company has a 12 month low of $64.18 and a 12 month high of $89.09. The stock has a market capitalization of $91,236.74, a P/E ratio of 20.26, a PEG ratio of 1.83 and a beta of 0.34.

Eli Lilly and (NYSE:LLY) last posted its earnings results on Tuesday, October 24th. The company reported $1.05 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.03 by $0.02. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. The firm had revenue of $5.66 billion for the quarter, compared to analysts’ expectations of $5.52 billion. During the same period in the previous year, the firm earned $0.88 earnings per share. The business’s revenue was up 9.0% compared to the same quarter last year. sell-side analysts anticipate that Eli Lilly and Company will post 4.22 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, December 8th. Stockholders of record on Wednesday, November 15th will be paid a dividend of $0.52 per share. The ex-dividend date is Tuesday, November 14th. This represents a $2.08 annualized dividend and a dividend yield of 2.52%. Eli Lilly and’s dividend payout ratio (DPR) is presently 98.58%.

Eli Lilly and Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.